Guselkumab
Guselkumab is a pharmaceutical drug with 71 clinical trials. Currently 30 active trials ongoing. Historical success rate of 81.8%.
Success Metrics
Based on 27 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
13
Mid Stage
40
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.1%
27 of 35 finished
22.9%
8 ended early
30
trials recruiting
71
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Clinical Trials (71)
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 71